Insuman Basal

Insulin human, the active ingredient in Insuman Basal, is an insulin presented as a solution for injection for subcutaneous use. It treats hyperglycaemia in patients with Type 1 and Type 2 diabetes mellitus. GNH USA supplies Insuman Basal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Insuman Basal provides basal insulin therapy for diabetes management. - Type 1 diabetes mellitus: supplies long‑acting insulin to maintain fasting glucose levels. - Type 2 diabetes mellitus: supplements endogenous insulin to improve overall glycaemic control. - Diabetes requiring basal insulin supplementation: offers steady insulin coverage when oral agents are insufficient.

Insuman Basal may cause adverse reactions typical of insulin therapy.

Common Side Effects: - Hypoglycaemia: low blood glucose episodes, especially if dosing is excessive. - Injection site reactions: redness, swelling or itching at the injection site. - Weight gain: increased adipose tissue due to improved glucose utilisation. - Lipodystrophy: localized changes in subcutaneous fat with repeated injections. - Edema: mild fluid retention in extremities.

Serious or Rare Side Effects: - Severe hypoglycaemia: neuroglycopenic symptoms requiring immediate assistance. - Allergic reactions: urticaria, rash, or anaphylaxis. - Insulin antibodies: may alter insulin effectiveness. - Acute metabolic acidosis: rare but serious metabolic disturbance. - Stevens‑Johnson syndrome: severe skin reaction, though extremely uncommon.

When using Insuman Basal, consider the following safety measures. - Dose individualisation: adjust dose based on regular blood glucose monitoring. - Hypoglycaemia risk: educate patients on recognising and treating low blood sugar. - Concomitant illnesses: modify therapy during infection, surgery or renal/hepatic impairment. - Pregnancy and lactation: use only if benefits outweigh potential risks; category not established. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insuman Basal can interact with several drug classes.

Major Interactions (Avoid): - Other insulin products: additive hypoglycaemic effect. - Meglitinides (e.g., repaglinide): increased risk of severe hypoglycaemia. - Beta‑blockers: may mask hypoglycaemia symptoms.

Moderate Interactions (Monitor Closely): - Oral antidiabetic agents (metformin, sulfonylureas): may potentiate glucose‑lowering effect. - ACE inhibitors and ARBs: can enhance insulin sensitivity. - Diuretics: may affect potassium levels influencing insulin action. - Corticosteroids: may increase insulin requirements. - Alcohol: can cause unpredictable glucose fluctuations.